SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
SAN FRANCISCO — After 7 years, transcatheter aortic valve replacement (TAVR) remains equivalent to surgery with respect to durability and safety in low-risk patients, a finding that may blunt ...
WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...
Edwards Lifesciences secures FDA clearance for its ECLIPTIS Left Atrial Appendage Exclusion System, entering a competitive ...
In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results